News – Alligator Bioscience

2024-09-16

Alligator Bioscience and Aptevo Therapeutics Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study

Early Data Indicate Clinical Activity in Patients with Multiple Solid Tumor Types Prolonged stable disease lasting >11 months demonstrate ...

2024-09-13

Lund, Sweden and Seattle, Washington, September 13, 2024 – Alligator Bioscience AB (“Alligator”) (Nasdaq Stockholm: ATORX) ...

2024-07-112024-07-11

Regulatory

Substantial overall survival benefit and unprecedented Duration of Response reported in 18-month analysis from mitazalimab OPTIMIZE-1 Phase ...

2024-07-10

Recruitment completed for the additional cohort with 450 µg/kg of mitazalimab in combination with mFOLFIRINOX as requested by FDA ahea ...

2024-06-26

Regulatory

Median Overall Survival increased to 14.9 months and survival rate at 18 months was 36.2%, nearly twice as high as the 18.6% previously repo ...

2024-06-25

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

2024-06-20

Primary endpoint of OPTIMIZE-1 trial was met, with Objective Response Rate (ORR) of 40.4% in 57 evaluable patients Unprecedented Duration of ...

2024-06-14

Regulatory

Lund, Sweden, June 14, 2024 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces the appointment of Johan Giléus as ...

2024-06-03

Publication in world-leading clinical oncology journal validates the quality and potential implications of Phase 2 OPTIMIZE-1 results The st ...